慢性髓系白血病合并传染病的规范化管理进展

黎纬明; 余甜

doi:10.13201/j.issn.1004-2806.2023.05.004

慢性髓系白血病合并传染病的规范化管理进展

黎纬明^1, ,,
余甜²

- 1.
  华中科技大学同济医学院附属协和医院血液科(武汉，430022)
- 2.
  三峡大学医学院

详细信息

作者简介:
黎纬明，华中科技大学同济医学院附属协和医院血液科主任医师, 副教授，硕士生导师。担任中国医药教育协会白血病专业委员会常务委员，中国医药教育协会转化医学专业委员会常务委员，湖北省抗癌协会血液肿瘤青年委员会副主任委员，湖北省医学生物免疫学会血液专委会慢粒分会主任委员，武汉市质控中心白血病工作组组长，湖北省科普作家协会医学科普创作专委会内科分会主任委员，湖北省医学生物免疫学会第二届理事会常务理事，湖北省医学生物免疫学会转化医学专委会常务委员，武汉市和睿慢粒患者帮扶中心医学理事长。出版国内第一本慢粒相关患教书籍：《和黎医生一起认识慢粒》。参与格列卫全球患者援助项目(GIPAP)等多项慢粒相关慈善计划。参与国内外多项慢粒相关临床研究及武汉协和医院国际标准化PCR检测实验室的建立。先后参与并承担了多项国家及省级科研课题，在Leukemia、Haematologica、Cancer等国内外专业期刊上发表论文50余篇。参与获得多项省部级科技进步奖。主编或参编多部学术著作

通讯作者: 黎纬明，E-mail：lee937@126.com

中图分类号: R733.72

收稿日期: 2023-03-20

刊出日期: 2023-05-01

Management of chronic myelogenous leukemia with infectious diseases

LI Weiming^1, ,,
YU Tian²

- 1.
  Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- 2.
  Medical College of the Three Gorges University

More Information

Corresponding author: LI Weiming, E-mail: lee937@126.com

Received Date: 20 March 2023

Publish Date: 01 May 2023

摘要

摘要: 随着酪氨酸激酶抑制剂(tyrosine kinase inhibitors，TKI)的出现，慢性髓系白血病(chronic myeloid leukemia，CML)的预后得到了极大的改善，几乎不影响患者的正常寿命，达到长期生存。但目前普遍认为，TKI对机体的免疫系统仍存在一些独特的影响，患者处于一定的免疫抑制状态。传染病可在人群中流行，危害患者的健康甚至造成死亡，特别是近年来的COVID-19。因此，CML患者在长期生存过程中如何预防各种传染病？罹患传染病时的诊治原则与健康人群或其他血液病患者相比有无不同？相关大宗或前瞻性的研究仍较缺乏。本文结合近期的最新研究进展，重点关注CML患者合并COVID-19和乙肝相关问题，将有助于CML患者合并传染病的规范化管理，进一步提高CML患者的预后和生存质量。
- 慢性髓系白血病 /
- 酪氨酸激酶抑制剂 /
- 2019新型冠状病毒病 /
- 乙肝
Abstract: With the advent of tyrosine kinase inhibitors(TKI), the prognosis of chronic myeloid leukemia(CML) has been greatly improved, achieving long-term survival with little impact on patients' normal life span. However, it is generally believed that TKI still has some unique effects on the body's immune system, and patients are in a certain state of immunosuppression. Infectious diseases, especially COVID-19 in recent years, can spread among people, harming their health and even causing death. Therefore, how can patients with CML prevent various infectious diseases in the course of long-term survival? Are the principles for the treatment of infectious diseases different from those of healthy people or patients with other blood diseases? Relevant bulk or prospective studies are still lacking. This review focus on issues related to COVID-19 and hepatitis B in patients with CML combined with the latest research progress, which will contribute to the standardized management of infectious diseases in patients with CML and further improve the prognosis and quality of life of patients with CML.
- chronic myelogenous leukemia /
- tyrosine kinase inhibitors /
- coronavirus disease 2019 /
- hepatitis B

HTML全文

参考文献(35)

[1]	中华医学会血液学分会感染学组, 中华医学会血液学分会淋巴细胞疾病学组, 中国临床肿瘤学会(CSCO)抗淋巴瘤联盟. 血液肿瘤免疫及靶向药物治疗相关性感染预防及诊治中国专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(9): 717-727.
[2]	Li WM, Wang DY, Guo JM, et al. COVID-19 in persons with chronic myeloid leukaemia[J]. Leukemia, 2020, 34(7): 1799-1804. doi: 10.1038/s41375-020-0853-6
[3]	Ector GICG, Huijskens EGW, Blijlevens NMA, et al. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study[J]. Leukemia, 2020, 34(9): 2533-2535. doi: 10.1038/s41375-020-0964-0
[4]	Breccia M, Abruzzese E, Accurso V, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report[J]. Br J Haematol, 2022, 196(3): 559-565. doi: 10.1111/bjh.17890
[5]	中国康复医学会血液病康复专业委员会, 中华医学会血液学分会. 成人血液病患者接种新型冠状病毒疫苗中国专家共识(2022年版)[J]. 中华血液学杂志, 2022, 43(5): 359-364.
[6]	Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016, 15(5): 327-347. doi: 10.1038/nrd.2015.37
[7]	国家卫生健康委办公厅, 国家中医药局综合司. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[EB/OL]. (2023-01-05)[2023-01-28]. http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml.
[8]	Bonifacio M, Tiribelli M, Miggiano MC, et al. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population[J]. Cancer Med, 2021, 10(18): 6310-6316. doi: 10.1002/cam4.4179
[9]	Claudiani S, Apperley JF, Parker EL, et al. Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors[J]. Br J Haematol, 2022, 197(1): e1-e4.
[10]	Yang YF, Zhang YL, Jiang Q, et al. Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China[J]. Chin Med J(Engl), 2022, 135(12): 1498-1499.
[11]	国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种技术指南(第1版)[J]. 中国病毒病杂志, 2021, 11(3): 161-162.
[12]	Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia(ECIL 9)[J]. Leukemia, 2022, 36(6): 1467-1480. doi: 10.1038/s41375-022-01578-1
[13]	Mariana L, Florencia B, David G, et al. Sub-Analysis of Patients with COVID-19 in Chronic Myeloid Leukemia on TKI Treatment: Update from the International CML Foundation(iCMLf)CML and COVID-19 Study[C]. 2022.
[14]	Tanaka A, Nishikawa H, Noguchi S, et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells[J]. J Exp Med, 2020, 217(2): e20191009. doi: 10.1084/jem.20191009
[15]	Saußele S, Evans N, Nicolini FE, et al. p701: covid-19 in patients with chronic myeloid leukemia in treatment-free remission: disease severity and impact on tfr status[J]. HemaSphere, 2022, 6: 596-597. doi: 10.1097/01.HS9.0000845688.87868.5c
[16]	Récoché I, Rousseau V, Bourrel R, et al. Drug-drug interactions with imatinib: an observational study[J]. Medicine, 2016, 95(40): e5076. doi: 10.1097/MD.0000000000005076
[17]	Talpaz M, Silver R, Druker B, et al. A Phase Ⅱ study of STI571 in adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia on accelerated phase[J]. Blood, 2000, 96(suppl 1): 469a.
[18]	US Food and Drug Administration. July-September 2016 report: potential signals of serious risks/new safety information identified by the FDA Adverse Event Reporting System(FAERS)[EB/OL]. (2020-04-16)[2021-02-08]. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2016-report-potential-signals-serious-risksnew-safety-information-identified-fda.
[19]	Uhm J, Klm SH, Oh S, et al. High incidence of hepatitis B viral reactivation in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors[J]. Blood, 2018, 132: 3010. doi: 10.1182/blood-2018-99-117543
[20]	Kim SH, Kim HJ, Kwak JY, et al. Hepatitis B virus reactivation in chronic myeloid leukemia treated with various tyrosine kinase inhibitors: multicenter, retrospective study[J]. Blood, 2012, 120(21): 3738. doi: 10.1182/blood.V120.21.3738.3738
[21]	Wang YH, Liang JD, Sheng WH, et al. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-Experience in 142 adult patients with chronic myeloid leukemia[J]. Leuk Res, 2019, 81: 95-97. doi: 10.1016/j.leukres.2019.05.001
[22]	Sorà F, Ponziani FR, Laurenti L, et al. Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors[J]. Leuk Lymphoma, 2017, 58(4): 993-995. doi: 10.1080/10428194.2016.1219906
[23]	Lai GM, Yan SL, Chang CS, et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor[J]. World J Gastroenterol, 2013, 19(8): 1318-1321. doi: 10.3748/wjg.v19.i8.1318
[24]	Ando T, Kojima K, Isoda H, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia[J]. Int J Hematol, 2015, 102(3): 379-382. doi: 10.1007/s12185-015-1788-y
[25]	Rajala HLM, Missiry ME, Ruusila A, et al. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia[J]. J Cancer Res Clin Oncol, 2017, 143(8): 1543-1554. doi: 10.1007/s00432-017-2378-6
[26]	Lee HW, Lee JS, Ahn SH. Hepatitis B virus cure: targets and future therapies[J]. Int J Mol Sci, 2020, 22(1): 213. doi: 10.3390/ijms22010213
[27]	Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment[J]. Leuk Lymphoma, 2006, 47(1): 155-157. doi: 10.1080/14639230500236818
[28]	Mohty M, Jourdan E, Mami NB, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia[J]. Blood, 2004, 103(12): 4666-4668. doi: 10.1182/blood-2003-09-3220
[29]	Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy[J]. Hepatol Int, 2021, 15(5): 1031-1048. doi: 10.1007/s12072-021-10239-x
[30]	Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. doi: 10.1002/hep.29800
[31]	Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology, 2015, 148(1): 215-219;quize 16-17. doi: 10.1053/j.gastro.2014.10.039
[32]	European Association for the Study of the Liver Electronic address: easloffice@easloffice eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
[33]	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华临床感染病杂志, 2019, 12(6): 401-428. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD201912010.htm
[34]	中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191.
[35]	Huang H, Li XY, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial[J]. JAMA, 2014, 312(23): 2521-2530. doi: 10.1001/jama.2014.15704